Moebius Medical
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Medical device or technology
In conjunction with our licensee Sun Pharma, Moebius is developing MM-II, a novel, Phase 3 and CE-Mark ready, non-opioid, non-hyaluronic acid, treatment for osteoarthritis.
MM-II has successfully completed a global Phase 2 study with promising results, and received FDA alignment for Phase 3. In Europe, MM-II is classified as a medical device and has fulfilled all clinical requirements for marketing authorization.
While our licensing partner Sun Pharma holds exclusive rights for human indications, Moebius has retained veterinary rights and will be exploring collaborations with companies active in the veterinary space.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}